// App-Quantinova.ai

LB02 : Frexalimab, a CD40L Inhibitor, in Relapsing Multiple Sclerosis: Results from a Randomized Controlled Phase 2 Trial

Researchers

Presenter

  • Patrick Vermersch

Principal Investigators

  • Cristina Granziera

  • Yang Mao-Draayer

  • Gary Cutter

  • Oleksandr Kalbus

  • Ivan Staikov

  • Michal Dufek

  • Stephane Saubadu

  • Raphael Bejuit

  • Philippe Truffinet

  • Erik Wallstroem

  • Gavin Giovannoni

Medical Centers

  • Acibadem City Clinic University Hospital Tokuda

  • Queen Mary University, London, UK

  • University Hospital Basel, University of Basel

  • Dnipro State Medical University

  • CHU Lille, FHU Precise

  • University of Michigan Medical Center, Michigan

  • St. Vincent’s University Hospital

  • Yale School of Public Health,

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • NCT04879628

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved